| Bioactivity | RORγt inverse agonist 13 (Compound 3i) is a potent, orally active and selective RORγt inverse agonist, with improved drug-like properties, with an IC50 of 63.8 nM[1]. | |||||||||
| Invitro | RORγt inverse agonist 13 (Compound 3i) exhibits activity with an inhibition of 76% at 0.3 µM in Th17 cell differentiation assay[1]. | |||||||||
| In Vivo | RORγt inverse agonist 13 (Compound 3i, 25 mg/kg, Orally, twice daily) demonstrats excellent in vivo PK profile in mice and good in vivo efficacy in an IMQ-induced psoriasis mice model[1]. Animal Model: | |||||||||
| Name | RORγt inverse agonist 13 | |||||||||
| CAS | 2170477-75-3 | |||||||||
| Formula | C23H17Cl2F3N2O4 | |||||||||
| Molar Mass | 513.29 | |||||||||
| Appearance | Solid | |||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | |||||||||
| Storage |
|
|||||||||
| Reference | [1]. Nannan Sun, et al. Discovery of carboxyl-containing biaryl ureas as potent RORγt inverse agonists. Eur J Med Chem. 2020 Jul 5;202:112536. |
RORγt inverse agonist 13
CAS: 2170477-75-3 F: C23H17Cl2F3N2O4 W: 513.29
RORγt inverse agonist 13 (Compound 3i) is a potent, orally active and selective RORγt inverse agonist, with improved d
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.